The latest price target for NLS Pharmaceutics (NASDAQ:NLSP) was reported by Maxim Group on September 14, 2023. The analyst firm set a price target for $0.00 expecting NLSP to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for NLS Pharmaceutics (NASDAQ:NLSP) was provided by Maxim Group, and NLS Pharmaceutics downgraded their hold rating.

The last upgrade for NLS Pharmaceutics Ltd happened on December 8, 2022 when Maxim Group raised their price target to $4. Maxim Group previously had a hold for NLS Pharmaceutics Ltd.

The last downgrade for NLS Pharmaceutics Ltd happened on September 14, 2023 when Maxim Group changed their price target from N/A to N/A for NLS Pharmaceutics Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NLS Pharmaceutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NLS Pharmaceutics was filed on September 14, 2023 so you should expect the next rating to be made available sometime around September 14, 2024.

While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a downgraded with a price target of $0.00 to $0.00. The current price NLS Pharmaceutics (NLSP) is trading at is $3.13, which is out of the analyst’s predicted range.